8-K: Chain Bridge I to Acquire Phytanix Bio, Creating a New Public Company Focused on Developing Next Generation Cannabinoid and Cannabinoid-like Medicines

Phytanix Bio, a preclinical stage pharmaceutical company specializing in cannabinoid and cannabinoid-like medicines, is set to merge with Chain Bridge I, a special purpose acquisition company, to become a publicly listed entity.

Summary

• Phytanix Bio, a pharmaceutical company focused on cannabinoid and cannabinoid-like therapeutics, has agreed to a business combination with Chain Bridge I (CBRG), a special purpose acquisition company.
• The transaction values Phytanix Bio at $58 million, plus the assumption of $17 million in preferred stock and $4.4 million in short-term debt, which will be exchanged for convertible preferred stock at closing.
• The combined company, to be named Phytanix Inc., is expected to list on the Nasdaq Capital Market under the ticker symbol PHYX.
• The merger is anticipated to close in the fourth quarter of 2024, pending shareholder approvals.
• The new company will be led by Phytanix Bio's founders, including Barrett Evans as CEO, Colin Stott as COO, and Dominic Schiller leading legal and IP strategy.
• Phytanix Bio aims to develop new medicines using botanically inspired active pharmaceutical ingredients, focusing on therapeutic areas such as treatment-resistant facial seizures and Painful Bladder Syndrome (PBS).
• The combined company expects to use the resources from the transaction to advance its lead product candidates into clinical trials.
• The transaction is not subject to a minimum cash condition, and the parties intend to seek additional financing over time.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the potential of Phytanix Bio's technology and the experience of its management team. The transaction is presented as a strategic move to bring innovative cannabinoid-based medicines to market. However, there are some risks and uncertainties associated with the transaction, such as the need for additional capital and the success of clinical trials.

Positives

• The merger combines Phytanix Bio's innovative approach to cannabinoid therapeutics with CBRG's public market access.
• Phytanix Bio's management team has a proven track record in developing and commercializing cannabinoid-based medicines.
• The company has a well-defined pipeline targeting specific unmet medical needs.
• The transaction provides Phytanix Bio with the necessary capital to advance its lead product candidates into clinical trials.
• The combined company is expected to be listed on Nasdaq, providing increased visibility and access to capital markets.

Negatives

• The transaction is subject to shareholder approvals and other closing conditions.
• The combined company will need to raise additional capital to fully fund its operations and clinical trials.
• The company is still in the preclinical stage, and there is no guarantee that its lead product candidates will be successful in clinical trials or receive regulatory approval.
• The transaction is not subject to a minimum cash condition, which could result in less cash available to the combined company if CBRG shareholders redeem their shares.

Risks

• The transaction may not close if shareholder approvals are not obtained or other closing conditions are not met.
• The combined company may not be able to raise sufficient additional capital to fund its operations and clinical trials.
• The company's lead product candidates may not be successful in clinical trials or receive regulatory approval.
• The company may face competition from other companies developing cannabinoid-based medicines.
• The company's success depends on its ability to protect its intellectual property and maintain its competitive advantage.

Future Outlook

The combined company will focus on advancing its lead product candidates into clinical trials, targeting treatment-resistant facial seizures and Painful Bladder Syndrome (PBS). The parties intend to seek additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time.

Management Comments

• Barrett Evans, CEO of Phytanix, stated that the company has the necessary IP, scientific acumen, expertise, and management experience to create a new generation of medicines.
• Andrew Cohen, CEO of CBRG, expressed his delight in merging with Phytanix Bio, citing the team's depth of experience in developing cannabinoid medicines.

Industry Context

This announcement reflects the growing interest and investment in the cannabinoid-based pharmaceutical sector, with companies seeking to develop new therapies for various medical conditions. The merger of a SPAC with a preclinical stage pharmaceutical company is a common strategy to bring innovative technologies to the public market.

Comparison to Industry Standards

• The transaction is similar to other SPAC mergers in the biotech sector, where companies with promising technologies seek public funding and market access.
• Phytanix Bio's focus on botanically inspired active pharmaceutical ingredients aligns with the trend of developing more targeted and effective therapies.
• The management team's experience at GW Pharmaceuticals, a company that successfully developed and commercialized cannabinoid-based medicines, provides a strong foundation for Phytanix Bio's future success.
• The pre-deal valuation of $58 million for Phytanix Bio is within the range of other preclinical stage biotech companies that have gone public through SPAC mergers.
• The assumption of $17 million in preferred stock and $4.4 million in short-term debt is a common practice in SPAC mergers, where the target company's existing liabilities are often restructured.

Management Changes

Stakeholder Impact

• Shareholders of CBRG will have the opportunity to vote on the proposed transaction.
• Shareholders of Phytanix Bio will receive HoldCo shares in exchange for their existing shares.
• Employees of Phytanix Bio will become employees of the combined company.
• Customers and suppliers of Phytanix Bio will be impacted by the merger.
• Creditors of Phytanix Bio will be impacted by the assumption of debt and the exchange for convertible preferred stock.

Next Steps

• CBRG and Phytanix Bio will seek shareholder approvals for the transaction.
• The combined company will file a registration statement on Form S-4 with the SEC.
• The parties will work to complete the transaction in the fourth quarter of 2024.
• The combined company will seek additional financing over time.
• The combined company will advance its lead product candidates into clinical trials.

Key Dates

Keywords

Phytanix Bio, Chain Bridge I, cannabinoid, pharmaceutical, merger, acquisition, Nasdaq, biotechnology, drug development, clinical trials, IP, healthcare